CA-ATLASSIAN
4.3.2014 17:04:44 CET | Business Wire | Pressemeddelelse
Atlassian , a leading provider of collaboration software for teams, today announced Atlassian Connect - an extensible new framework for developers to build add-ons that deeply integrate with Atlassian JIRA OnDemand and Atlassian Confluence OnDemand, the company's cloud-based issue tracking and collaboration offerings. Developers can offer these add-ons to Atlassian's 33,000 customers via the Atlassian Marketplace , a proven ecosystem of more than 1,500 commercial and free add-ons. Since the Atlassian Marketplace launched in 2012, third party add-on developers who have sold products via the platform have earned more than $20 million.
"Customer demand for customized add-ons to our cloud-based JIRA and Confluence offerings has been incredible," said Nick Wade, director of Atlassian Marketplace. "With our next generation development framework – Atlassian Connect – third-party developers can now easily create secure and scalable add-ons for millions of Atlassian cloud-based customers and sell their products via our marketplace. We’re thrilled to help fellow developers build their own businesses."
Click to tweet : "Announcing @Atlassian Connect, the next generation of add-ons for No. JIRA and No. Confluence OnDemand http://ow.ly/ucD4I"
The new Atlassian Connect framework, built on common web standards like REST APIs and JWT authentication, offers additional modules for developers to integrate add-ons directly into Atlassian applications using the technology stack of their choice. Third-party partners like Zendesk, Lucidchart, Gliffy, Zephyr, and Comalatech are among the early adopters of Atlassian Connect. Today 15 publicly available add-ons for Atlassian JIRA and Confluence OnDemand are already in use by more than 600 companies.
"The streamlined discovery and procurement experience offered by marketplaces accelerates the consumption of applications - making it a win/win for both customer and developer, as the mobile market has more than adequately demonstrated," said Stephen O'Grady, principal analyst with RedMonk. "Atlassian has invested heavily in this area, and with Atlassian Connect is attempting to dramatically expand the reach of its Marketplace to the cloud."
"We see Atlassian Connect as an opportunity to re-architect our successful diagramming and mockup tool for JIRA," said Chris Kohlhardt, CEO of Gliffy. "Based on Atlassian Connect, the next version of Gliffy for JIRA OnDemand will maintain the same intuitive interface and we'll be able to deploy product improvements instantly."
Rich platform for developers
Atlassian Connect provides rich user interface integration and continuous two-way communication to create smoother end-to-end experiences for customers. Specifically, Atlassian Connect offers:
- Simple descriptors: Any web application – written in any language – can become an Atlassian Connect add-on by providing a simple JSON file to describe itself to Atlassian applications. Atlassian has already built client libraries for node.js and the Play framework to make getting started even easier.
- User interface modules: Atlassian Connect provides almost two dozen different UI integration points, such as issue panels, page macros, and fullscreen pages for add-ons to insert content directly into the Atlassian application.
- Two-way communication : Atlassian Connect add-ons can pull data and push data back using JIRA or Confluence's REST APIs, listen for events with webhooks, and recognize different users via JWT authentication.
Training/Availability
Atlassian will provide extensive training and discussion of Atlassian Connect at its upcoming eighth annual developer conference, AtlasCamp , to be held June 3-5 in Berlin, Germany. For more information, go to www.atlassian.com/AtlasCamp . Developers interested in building Atlassian Connect add-ons for public distribution or private use can access developer tutorials and documentation at connect.atlassian.com .
Newly available add-ons for JIRA and Confluence OnDemand built using Atlassian Connect include:
- Zendesk for JIRA: Seamlessly escalate Zendesk tickets to JIRA to keep customer support, developers, and product managers all in sync
- EazyBI for JIRA: A powerful business intelligence tool with drag-and-drop creation of pivot tables and charts based on JIRA data
- Canvas for Confluence and JIRA: Interactive boards help teams collaborate visually: create issues or pages, drag to organize by field attribute or label, and filter
- Harvest Time Tracking for JIRA: Integration between JIRA and the Harvest time tracking platform so users can track time on JIRA issues from within JIRA
- Ink File Picker for Confluence: Allows Confluence users to attach files to pages from over a dozen cloud storage services, including Box, Dropbox, Google Drive, and SkyDrive
- Aha! Product Roadmaps for JIRA: Create product strategy and visual roadmaps in Aha! and move epics and stories into JIRA to be developed
Developer tutorials and documentation are available at connect.atlassian.com .
About Atlassian
Atlassian products help innovators everywhere plan, build and launch great software. More than 33,000 large and small organizations – including Citigroup, eBay, Coca-Cola, Netflix and United Airlines – use Atlassian’s issue tracking, collaboration and software-development products to work smarter and deliver quality results on time. Learn more at http://atlassian.com .
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20140304005805/en/
Contact:
Atlassian
Aaron Forman, 415-701-1110 ext. 4450
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum